Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
Authors: Joong Won Park
Deepak Amarapurkar
Yee Chao
Pei Jer Chen
Jean Francois H. Geschwind
Khean Lee Goh
Kwang Hyub Han
Masatoshi Kudo
Han Chu Lee
Rheun Chuan Lee
Laurentius A. Lesmana
Ho Yeong Lim
Seung Woon Paik
Ronnie T. Poon
Chee Kiat Tan
Tawesak Tanwandee
Gaojun Teng
Ann Lii Cheng
National Cancer Center, Gyeonggi
Bombay Hospital and Medical Research Centre
Veterans General Hospital-Taipei
National Taiwan University College of Medicine
The Johns Hopkins School of Medicine
University of Malaya
Yonsei University College of Medicine
Kindai University School of Medicine
University of Ulsan, College of Medicine
Universitas Indonesia
Samsung Medical Center, Sungkyunkwan University
SungKyunKwan University, School of Medicine
The University of Hong Kong
Singapore General Hospital
Mahidol University
Southeast University
National Taiwan University Hospital
Keywords: Medicine
Issue Date: 1-Jan-2013
Citation: Liver International. Vol.33, No.3 (2013), 327-337
Abstract: Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens. © 2013 John Wiley & Sons A/S.
ISSN: 14783231
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.